Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463597 | 0.88 | ALDH1A1 (0.61) | HDAC1HDAC3HDAC2MAPK1PTGS1 | |
| SCHEMBL29904721 | 0.88 | ALDH1A1 (0.61) | HDAC1HDAC3HDAC2MAPK1PTGS1 | |
| Hydrochloric Acid SCHEMBL11503558 | 0.86 | HDAC1 (0.59) | HDAC1HDAC3HDAC2MAPK1PTGS1 | |
| Tacedinaline SCHEMBL248074 | 0.85 | HDAC1 (0.66) | HDAC1HDAC3HDAC2MAPK1PTGS1 | |
| Aniline SCHEMBL22169226 | 0.84 | HDAC1 (0.58) | HDAC1HDAC3HDAC2MAPK1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3600528 | 0.81 | SIRT2 (0.57) | ALDH1A1HPGDNPC1RAB9APOLB | |
| Trifluoroacetic Acid SCHEMBL8887269 | 0.81 | SMN1; SMN2 (0.46) | HDAC1HDAC3HDAC2MAPK1ALDH1A1 | |
| SCHEMBL3846828 | 0.79 | PTGS1 (0.58) | HDAC1HDAC3HDAC2MAPK1PTGS1 | |
| Acetanilide SCHEMBL6388813 | 0.77 | NAPRT (0.76) | MAPK1ALDH1A1NPC1RAB9APOLB | |
| SCHEMBL12075892 | 0.77 | HDAC1 (0.63) | HDAC1HDAC3HDAC2MAPK1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121612-B1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2014-10-01 | — | — | EP | disclosed |
| US-8299102-B2 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2012-10-30 | — | — | US | disclosed |
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2121612-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008080511-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | WO | disclosed |
| EP-1942104-A1 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | PTGIS, TBXAS1, EDNRA | HDAC1 1647/4885HDAC3 1361/4885HDAC2 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.